A innovative monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – represents considerable opportunity in the therapy of acute immune reaction (TRALI). Created by Bio-X, Pritoxaximab functions by https://www.targetmol.com/compound/pritoxaximab